Get the Stockscreener App
100.35
1.28%
1.27
After Hours:
100.90
0.55
+0.55%
Celcuity Inc stock is traded at $100.35, with a volume of 852.05K.
It is up +1.28% in the last 24 hours and up +41.40% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$99.08
Open:
$100
24h Volume:
852.05K
Relative Volume:
0.79
Market Cap:
$4.64B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-37.44
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+6.49%
1M Performance:
+41.40%
6M Performance:
+861.21%
1Y Performance:
+668.97%
1-Day Range:
$97.74
$101.36
1-Week Range:
$92.10
$103.06
52-Week Range:
$7.575
$103.06
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
100.35 | 4.58B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results - The Motley Fool
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results - The Motley Fool
(CELC) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
How Celcuity Inc. stock reacts to job market dataJuly 2025 Macro Moves & Free Community Consensus Stock Picks - BỘ NỘI VỤ
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference - The Manila Times
Celcuity Inc. to Participate in 8th Annual Evercore Healthcare Conference with CEO Fireside Chat Scheduled for December 3, 2025 - Quiver Quantitative
Celcuity Inc. (CELC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Jefferies reiterates Buy rating on Celcuity stock ahead of cancer data - Investing.com India
Jefferies reiterates Buy rating on Celcuity stock ahead of cancer data By Investing.com - Investing.com South Africa
What analysts say about Celcuity Inc stockMarket Sentiment Indicators & Learn to Trade Without Fear of Loss - earlytimes.in
Celcuity (CELC)'s Clinical Success and M&A Potential Underpin Wolfe Research's Bullish View - Finviz
Celcuity (CELC)’s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View - Insider Monkey
Celcuity (CELC) Price Target Increased by 16.06% to 97.66 - MSN
Celcuity Director Unloads Shares in a Major Stock Sale! - TipRanks
Celcuity Insider Sold Shares Worth $377,255, According to a Recent SEC Filing - MarketScreener
Dir Buller Sells 3,900 ($377.3K) Of Celcuity Inc [CELC] - TradingView
Dir Dalvey Files To Sell 15,000 Of Celcuity Inc [CELC] - TradingView
Celcuity (CELC) Is Up 9.3% After FDA NDA Submission for Gedatolisib in Breast Cancer TherapyHas The Bull Case Changed? - simplywall.st
Why Celcuity Inc. stock is popular among millennials2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
Celcuity initiated with an Outperform at Wolfe Research - MSN
Celcuity submits gedatolisib new drug application to the FDA - MSN
Celcuity Inc. (CELC) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Celcuity stock reaches all-time high of 96.56 USD By Investing.com - Investing.com Canada
How institutional buying supports Celcuity Inc. stock2025 Retail Activity & Fast Gain Swing Trade Alerts - newser.com
How currency fluctuations impact Celcuity Inc. stock2025 Momentum Check & Expert Verified Movement Alerts - newser.com
Price action breakdown for Celcuity Inc.July 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Wolfe Research Initiates Coverage of Celcuity (CELC) with Outperform Recommendation - MSN
Key resistance and support levels for Celcuity Inc.2025 Price Momentum & Community Driven Trade Alerts - newser.com
Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited ReviewWhat's Changed - Yahoo Finance
When is the best time to exit Celcuity Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
How to track smart money flows in Celcuity Inc.July 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
Celcuity outlines $2.5B–$3B peak revenue potential for gedatolisib amid accelerated launch preparations - MSN
Wolfe Research initiates coverage on Celcuity stock with Outperform rating By Investing.com - Investing.com South Africa
Celcuity downgraded to Neutral from Buy at H.C. Wainwright - MSN
Wolfe Research initiates coverage on Celcuity stock with Outperform rating - Investing.com India
Celcuity Submits NDA for Gedatolisib to FDA - TipRanks
Celcuity Inc Submits NDA for Gedatolisib to FDA - TradingView
Celcuity Submits New Drug Application for Gedatolisib to Treat Breast Cancer - MarketScreener
Celcuity Inc. Submits New Drug Application for Gedatolisib to Treat Advanced Breast Cancer - Quiver Quantitative
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer - The Manila Times
Celcuity (Nasdaq: CELC) completes FDA NDA for gedatolisib, cutting progression risk by 76% - Stock Titan
Celcuity Shares Fall After HC Wainwright Downgrade - MarketScreener
Celcuity dips as H.C. Wainwright downgrades to 'neutral' - TradingView
Celcuity Analyst No Longer Bullish Despite Breast Cancer Therapy ApplicationCelcuity (NASDAQ:CELC) - Benzinga
HC Wainwright Downgrades Celcuity to Neutral From Buy, Adjusts PT to $94 From $77 - MarketScreener
HC Wainwright Downgrades Celcuity to Neutral From Buy, Price Target is $94 - MarketScreener
Liquidity Mapping Around (CELC) Price Events - news.stocktradersdaily.com
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):